[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369478-105":59,"doc-detail-369478-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","death-ision-the-link-between-cellular-resilience-and-cancer-resistance-to-treatments","Death-ision: the link between cellular resilience and cancer resistance to treatments","","Advanced tumors often defeat therapy by letting cancer cells evade chemotherapy, targeted therapy, immunotherapy, and cellular therapy pressures. Genetic and epigenetic alterations drive resistance, initially permitting survival after effective treatment responses. The article explains how regulatory mechanisms shape tumor-cell states and responsiveness across therapeutic strategies, proposing altered growth-versus-death balance as a core driver. It introduces Death-ision to capture how diverse, temporally and spatially constrained cell death programs determine whether clones resist or succumb, highlighting therapeutic opportunities and signaling pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/death-ision-the-link-between-cellular-resilience-and-cancer-resistance-to-treatments/369478/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/death-ision-the-link-between-cellular-resilience-and-cancer-resistance-to-treatments/369478.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main challenge in defeating advanced tumors described in the abstract?","Question",{"text":112,"@type":113},"Cancer cells evade the selective pressure imposed by multiple treatment modalities, allowing advanced tumors to resist therapies and persist.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do genetic and epigenetic alterations contribute to therapy resistance?",{"text":117,"@type":113},"They influence tumor-cell state and responsiveness, enabling survival after treatments that initially appear effective and supporting the development of resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the Death-ision framework aim to explain?",{"text":121,"@type":113},"It describes the dynamic regulation of cell death and how the balance of death-inducing signals versus survival mechanisms determines whether resistant clones evade therapy or succumb.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369478,1790611122,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Baldassarre etal. Molecular Cancer (2025) 24:144 [https://doi.org/10.1186/s12943-025-02339-1](https://doi.org/10.1186/s12943-025-02339-1)  \nMolecular Cancer  \n REVIEW Open Access  \nDeath-ision: the link between cellular  \nresilience and cancer resistance to treatments  \nGustavo Baldassarre1*†, Ivana [L. de](L. de) la Serna2*† and François M. Vallette3,4*†  \nAbstract  \nOne of the key challenges in defeating advanced tumors is the ability of cancer cells to evade the selective pressure imposed by chemotherapy, targeted therapies, immunotherapy and cellular therapies. Both genetic and epigenetic alterations contribute to the development of resistance, allowing cancer cells to survive initially effective treatments. In this narration, we explore how genetic and epigenetic regulatory mechanisms influence the state of tumor cells and their responsiveness to different therapeutic strategies. We further propose that an altered balance between cell growth and cell death is a fundamental driver of drug resistance. Cell death programs exist in various forms, shaped by cell type, triggering factors, and microenvironmental conditions. These processes are governed by temporal and spatial constraints and appear to be more heterogeneous than previously understood. To capture the intricate interplay between death-inducing signals and survival mechanisms, we introduce the concept of Death-ision. This framework highlights the dynamic nature of cell death regulation, determining whether specific cancer cell clones evade or succumb to therapy. Building on this understanding offers promising strategies to counteract resistant clones and enhance therapeutic efficacy. For instance, combining DNMT inhibitors with immune checkpoint blockade may counteract YAP1-driven resistance or the use of transcriptional CDK inhibitors could prevent or overcome chemotherapy resistance. Death-ision aims to provide a deeper understanding of the diversity and evolution of cell death programs, not only at diagnosis but also throughout disease progression and treatment adaptation.  \n†Gustavo Baldassarre, Ivana de la Serna and François M. Vallette these authors equally contributed to this work.  \n*Correspondence: Gustavo Baldassarre[gbaldassarre@cro.it](gbaldassarre@cro.it)[ ](gbaldassarre@cro.it)Ivana [L. de](L. de) la Serna  \n[Ivana.delaSerna@utoledo.edu](Ivana.delaSerna@utoledo.edu)[ ](Ivana.delaSerna@utoledo.edu)François M. Vallette  \nfrancois.vallette@univ-nantes.fr  \n1 Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Aviano 33081, Italy  \n2 Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA  \n3 Centre de Recherche en Cancérologie et Immunologie Intégrées Nantes Angers (CRCI2 NA), INSERM UMR1307/CNRS UMR 6075/Nantes Université/Univ. Angers. Nantes, 44007 Nantes, France  \n4 Institut de Cancérologie de L’Ouest (ICO), 44085 Saint-Herblain, France  \nIntroduction  \nCancer resistance to therapies along with its progression (including metastasis) are the causes of most failure in curing this disease. The “classical” theory is that cancer is initiated by sequential mutation(s) in normal cellular populations then undergoes a series of transformations which allow mutated cells to progress through rounds of selective processes, as suggested by Fearon and Vogelstein in the colorectal cancer context [1]. Some cancers are linked to genetic mutations but not all individuals with germinal cancerous mutations develop cancer. Heavy somatic mutation burdens found in cancer are also present in normal cellular ageing populations but not all these mutated cells develop into cancer [2].  \nCancer is an inherently ineffective disease (see Sect. 1) due to the existence of protective barriers (i.e. cell death or senescence) the failures of which initiate the onset and progression of cancer [3] . However,  \n© The Author(s) 2025. Open Access This article is lice","cbCaicNxjjLVtBE6","https://ap.wps.com/l/cbCaicNxjjLVtBE6","pdf",2543443,"English","# Introduction\n## Cancer resistance and tumor progression\n## Genetic, epigenetic changes, and treatment response","[{\"question\":\"What is the main challenge in defeating advanced tumors described in the abstract?\",\"answer\":\"Cancer cells evade the selective pressure imposed by multiple treatment modalities, allowing advanced tumors to resist therapies and persist.\"},{\"question\":\"How do genetic and epigenetic alterations contribute to therapy resistance?\",\"answer\":\"They influence tumor-cell state and responsiveness, enabling survival after treatments that initially appear effective and supporting the development of resistance.\"},{\"question\":\"What does the Death-ision framework aim to explain?\",\"answer\":\"It describes the dynamic regulation of cell death and how the balance of death-inducing signals versus survival mechanisms determines whether resistant clones evade therapy or succumb.\"}]","Death-ision: the link between cellular resilience and cancer resistance to treatments | PDF",1790182914,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bb67cd8ebe36aac95137465e03722ff.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10c9eefbbc96d9c15b956f3d95d09a7a.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9a95f2f23f0401dfeadf016aa95a974.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8697578214d7d59c37d03907f962abdc.webp",980,1301]